Home › Myelodysplastic Syndromes › New York › New York City
Myelodysplastic Syndromes clinical trials in New York City, NY
21 studies for Myelodysplastic Syndromes are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Montefiore, New York
Cord Blood Transplant in Adults With Blood Cancers
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
RecruitingPhase 3
- MSKCC, New York
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
RecruitingPhase 1
- NYU Langone Health, New York
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
RecruitingPhase 1/2
- Ichan School of Medicine at Mount Sinai, New York
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
RecruitingPhase 1/2
- Research Site, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- Perlmutter Cancer Center - 34th Street, New York
- Icahn School of Medicine at Mount Sinai, New York
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RecruitingPhase 1
- Icahn School of Medicine at Mount Sinai, New York
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
RecruitingPhase 1
- New York University, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, New York
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of REM-422 in Patients With AML or Higher Risk MDS
RecruitingPhase 1
- Memorial Sloan Kettering, New York
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RecruitingPhase 1
- Memorial Sloan-Kettering Cancer Center, New York
About Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) are rare. They are sometimes found during a routine blood test. Learn symptoms, risk factors, and treatment options.
More about Myelodysplastic Syndromes on MedlinePlus
Myelodysplastic Syndromes trials in other cities
- Houston, TX43 studies
- Baldwin Park, CA26 studies
- Seattle, WA21 studies
- Washington, DC20 studies
- Tampa, FL19 studies
- Boston, MA19 studies
- Miami, FL17 studies
- Columbus, OH14 studies
- Durham, NC14 studies
- St. Louis, MO13 studies
- Atlanta, GA13 studies
- Chicago, IL13 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.